Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis

Journal of the Neurological Sciences

Volumn 178, Issue 1, 2000, Pages 2-9

  Jeffery, Douglas R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Beta interferon; Clinical trials; Dose response; MRI; Multiple sclerosis; Outcome measures

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; INTERFERON BETA SERINE; PLACEBO;

ADULT; CALCULATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISABILITY; DISEASE ACTIVITY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; REGRESSION ANALYSIS; RELAPSE; REVIEW; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADJUVANTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 0034283528     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(00)00358-0     Document Type: Review

References (76)

1. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology. 13:1994;1-7.
2. Weinshenker B.G., Bass B., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. Brain. 112:1989;133-146.
3. Miller D.H., Hornabrook R.W., Purdie G. The natural history of multiple sclerosis:a regional study with some longitudinal data. J. Neurol. Neurosurg. Psych. 55:1992;341-346.
4. Matthews W.B. Course and prognosis. Matthews W.B., Acheson E.D., Batchelor J.R., Weller R.O. McAlpine's Multiple Sclerosis. 1985;49-72 Churchill Livingstone, NY.
5. Herndon R.M., Rudick R.A. Multiple sclerosis: the spectrum of severity. Arch. Neurol. 40:(9):1983;531-532.
6. Kermode A.G., Thompson A.J., Tofts P.S., MacManus D.G., Kendall B.E., Kingsley D.P.E., Mosely I.F., Rudge P., McDonald W.I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 113:1990;1477-1489.
7. Bastianello S., Pozzilli C., Bernardi S., et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurol. 40:1990;591-595.
8. Miller D.H., Rudge P., Johnson G., et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 111:1988;927-939.
9. Miller D.H. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol. 36:1994;S91-S94.
10. Thompson A.J., Miller D., Youl B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W.I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurol. 42:1992;60-63.
11. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. NEJM. 338:(5):1998;278-285.
12. Simon J.H., Jacobs L.D., Campion M.K., et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurol. 53:(1):1999;139-148.
13. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multi center, randomized, double-blind, placebo-controlled trial. Neurol 1993;43:655-61.
14. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurol 1995;45:1277-85.
15. Stone L.A., Frank J.A., Albert P.S., Bash C., Smith M.E., Maloni H., McFarland H.F. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Neurol. 37:1995;611-619.
16. Waubant E., Goodkin D.E., Sloan R., Andersson P.B. A pilot study of MRI activity before and during interferon beta-1a therapy. Neurol. 53:1999;874-876.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 1983:1444-52.
18. Weinshenker B.G., Ebers G.C. The natural history of multiple sclerosis. Can. J. Neurol. Sci. 14:1987;255-261.
19. Stevenson V.L., Leary S.M., Losseff N.A., et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurol. 51:1998;234-238.
20. Tartaglino L.M., Friedman D.P., Flanders A.E., et al. Multiple sclerosis in the spinal cord:MR appearance and correlation with clinical parameters. Radiology. 195:1995;725-732.
21. Riahi F., Zijdenbos A., Narayanan S., Arnold D., Francis G., Antel J., Evans A.C. Improved correlation between scores on the expanded disability status scale and cerebral lesion load in relapsing-remitting multiple sclerosis. Results of the application of new imaging methods. Brain. 121:(7):1998;1305-1312.
22. Losseff N.A., Webb S.L., O'Riordan J.I., et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progress. Brain. 119:1996;701-708.
23. Thorpe J.W., Kidd D., Moseley I.F., et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurol. 46:1996;373-378.
24. Youl B.D., Turano G., Miller D.H., et al. The pathophysiology of optic neuritis: An association of gadolinium leakage with clinical and electrophysiological deficits. Brain. 114:1991;2437-2450.
25. McFarland H.F. The lesion in multiple sclerosis:clinical, pathological, and magnetic resonance imaging considerations. J. Neurol. Neurosurg. and Psychiat. 64:(Suppl.):1998;S26-S30.
26. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Multiple Sclerosis. 5:1999;283-286.
27. Katz D., et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 34:1993;661-669.
28. Bruck W., et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 42:1997;783-793.
29. Nesbit G.M., et al. Multiple Sclerosis: histopathological and MR and/or CT correlation in 37 cases at biopsy and three at autopsy. Radiology. 180:1991;467-474.
30. Molyneux P.D., Filippi M., Barkhof F., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 43:(3):1998;332-339.
31. Filipi M., et al. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads. J. Neurol. Sci. 158:1998;203-208.
32. van Waesberghe J.H.T.M., van Walderveen M.A.A., Castelijns J.A., Scheltens P., Lycklama à Nijeholt G.J., Polman C.H., Barkhof F. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization MR. Am J Neuroradiol. 19:1998;675-683.
33. 1-weighted) spin-echo images. Neurol. 45:1995;1684-1690.
34. Truyen L., van Waesberghe J.H.T.M., van Walderveen M.A.A., van Oosten B.W., Polman C.H., Hommes O.R., Adèr H.J.A., Barkhof F. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurol. 47:1997;1469-1476.
35. van Walderveen M.A.A., et al. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis. Arch Neurol. 56:(3):1999;345-351.
36. van Waesberghe J.H., et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol. 19:1998;675-683.
37. Khoury S.J., Guttmann C.R.G., Orav E.J., Hohol M.J., Ahn S.S., Hsu L., Kikinis R., Mackin G.A., Jolesz F.A., Weiner H.L. Longitudinal MRI in multiple sclerosis. Neurol. 44:1994;2120-2124.
38. Smith M.E., et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetat dimeglumen-enhancing magnetic resonance imaging lesions. Ann Neurol. 33:1993;480-489.
39. Paty DW, Blumhardt LD. PRISMS Study Group. High-dose subcutaneous interferon β-1a is efficacious in transitional multiple sclerosis, a group at high risk of progression in disability. 123rd Annual Meeting of the American Neurological Association, October 1998, Montreal, Quebec, Canada.
40. Koudriavtseva T., Pozzilli C., Fiorelli M., et al. Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis. Multiple Sclerosis. 4:(5):1998;403-407.
41. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E. III, Priore R.I., Pullicino P.M., Scherokman B.J., Weinstock-Guttman B., Whitham R.H. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-292.
42. Paty D.W., Li D.K.B. the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multi center, randomized, double-blind, placebo-controlled trial. Neurol. 43:1993;662-667.
43. Freedman MS. OWIMS Study Group. Interferon β-1a in multiple sclerosis: dose-dependent clinical and MRI efficacy. American Neurological Association (ANA) 123rd Annual Meeting. Montreal, Quebec, Canada, October 18-21, 1998.
44. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1448-504.
45. European Study Group on Interferon β-1b in Secondary Progressive MS Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
46. Filipi M., et al. Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. Acta Neurol. Scand. 94:1994;93-93.
47. Tubridy N., et al. Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain. 121:1998;225-231.
48. Kidd D., et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J. Neurol. Neurosurg. Psych. 60:1996;15-19.
49. Stone L.A., Frank J.A., Albert P.S., Bash C.N., Calabresi P.A., Maloni H., McFarland H.R. Characterization of MRI response to treatment with interferon beta-1b: contrast enhancing MRI lesion for frequency as a primary outcome measure. Neurol. 49:1997;862-869.
50. Pachner A.R. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurol. 49:1997;647-650.
51. Filippi M., Rovaris M., Capra R., Gasperini C., Prandini F., Martinelli V., Horsfield M.A., Bastianello S., Sormani M.P., Pozzilli C., Comi G. Interferon β treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psych. 67:1999;386-389.
52. OWIMS. Evidence of interferon β-1a dose response in relapsing-remitting MS: The OWIMS Study. Neurol 1999;53:679-86.
53. Goodkin D.E. Commentary: Interferon β therapy for multiple sclerosis. Lancet. 352:1998;1486-1487.
54. Johnson K.P., Panitch H.S. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;494-498.
55. Goodin D.S. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;496.
56. Rice G., Ebers G. Interferons in the treatment of multiple sclerosis: Do they prevent the progression of the disease? Arch Neurol. 55:1998;1578-1579.
57. Herndon R.M., Jacobs L. Interferons should be used to treat most patients with MS. Arch Neurol. 55:1998;1581-1583.
58. Herndon R.M. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;494-495.
59. Galazka A. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;495.
60. O'Connor P. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;496.
61. Forbes R.B. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;496-497.
62. Ebers G.C. Interferon β treatment for multiple sclerosis. Lancet. 353:1999;497.
63. Ebers G.C., Paty D.W. Natural history studies and applications to clinical trials. Paty D.W., Ebers G.C. Multiple Sclerosis. 1998;192-228 F.A. Davis Company.
64. Blumhardt L. Interferon beta-1a in RRMS:A meta-analysis. American Neurological Association (ANA) 123rd Annual Meeting. Montreal, Quebec, Canada. P06.051, October 18-21, 1998.
65. Beutler E., Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 93:1996;1716-1720.
66. Polman C.H., Koetsler J.C. Cladribine treatment of multiple sclerosis. Lancet. 344:1994;537-538.
67. Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J., Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 344:1994;9-13.
68. Miller D.H., Barkhof F., Nauta J.J.P. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 116:1993;1077-1094.
69. 2-weighted brain MRI activity in multiple sclerosis:A follow-up study. Neurol. 45:1995;255-260.
70. Newcombe J., Hawkins C.P., Henderson C.L., Patel H.A., Woodroofe M.N., Hayes G.M., Cuzner M.L., MacManus D., du Boulay E.P.G.H., McDonald W.I. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain. 114:1991;1013-1023.
71. Newcombe J., Hawkins C.P., Henderson C.L., Woodroofe M.N., et al. Detection of multiple sclerosis by magnetic resonance imaging, macroscopic observation and histology in unfixed post-mortem CNS tissue. Neuropathol and Appl. Neurobiol. 15:1989;280-281.
72. Whitaker J.N., McFarland H.F., Rudge P., et al. Outcomes assessment in multiple sclerosis clinical trials:A critical analysis. Multiple Sclerosis. 1:1995;37-47.
73. Noseworthy J.H., Vandervoort M.K., Wong C.J., Ebers G.C. (Canadian Cooperative MS Study Group). Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurol. 40:1990;971-975.
74. Kappos L., Moeri D., Radue E.W., Schoetzau A., Schweikert K., Barkhof F., Miller D., Guttmann C.R.G., Weiner H.L., Gasperini C., Filippi M. for the Gadolinium MRI Meta-analysis Group. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis:A meta-analysis. Lancet. 353:1999;964-969.
75. O'Connor P. Comparison of outcome measures in Interferon beta studies in relapsing-remitting multiple sclerosis. Neurol. 52:(Suppl):1999;P06.052.
76. Simon J.H., Jacobs L.D., Campion M., Wende K., et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol. 43:1998;79-87.